Brittney de Clerck, MD
Dermatopathology · Los Angeles, CANPI 1477704856
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,950 of the $56,356 with a category attached, or 88.6%. Stemline Therapeutics Inc. accounts for 99.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $31,797 and has fallen 99.9% since, to $19 in 2025. Among dermatopathology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $939.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$56K
- AbbVie$119
- Mallinckrodt Enterprises LLC$119
- Tempus AI, Inc$28
What the payments were for
- Speaking & faculty fees$49,95089%
- Travel & lodging$5,0839%
- Food & beverage$1,3232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 52 | $56,090 |
| AbbVie | 6 | $119 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Tempus AI, Inc | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELZONRIS$44,706
- CELLEX/XTS PHOTOPHERESIS SYSTEM$119
How this compares
$56,356 in reported general payments places this provider in the 95th percentile of 76 dermatopathology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 16 | $1,089 |
| Ketoconazole | 20 | $256 |
| Triamcinolone Acetonide | 17 | $130 |
| Mupirocin | 17 | $48 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Los Angeles
- Emma TaylorLos Angeles$4K
- Stacey PunLos Angeles$3K
- Joshua MoLos Angeles$811
- Honggang ShenLos Angeles$474
- Nima AminiLos Angeles$305
- Zachary GoldsteinLos Angeles$223
- Gene KimLos Angeles$187
- Lyndon SuLos Angeles$135
- Christiane QuerfeldDuarte$107K
- Brook Brouhala Jolla$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.